Compare Affirm Holdings Inc (AFRM) vs ResMed Inc. (RMD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Affirm Holdings Inc vs ResMed Inc. — how do they compare? Affirm Holdings Inc trades at $80.06 (market cap $28.00B), while ResMed Inc. trades at $209.3 (market cap $31.88B). The key difference: Affirm Holdings Inc and ResMed Inc. are close in size by market cap, and ResMed Inc. pays a 1.09% dividend while Affirm Holdings Inc pays none. Which is the better fit depends on your goals.
| AFRM | RMD | |
|---|---|---|
Market Cap | $28.00B | $31.88B |
Sector | Financials | Health |
52-Week High | $92.18 | $293.73 |
52-Week Low | $42.53 | $182.82 |
Enterprise Value | $34.61B | $31.06B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AFRM trades at $83.62, down 1.14% on the day, with a bullish technical outlook supported by moving averages and a golden cross pattern. The company reported strong revenue growth, reaching $3.22 billion in 2025, and has consistently beaten earnings expectations in recent quarters. Recent partnerships with Bed Bath & Beyond and Backcountry expand its merchant network, driving transaction volume growth.
The outlook remains positive with analyst consensus favoring a buy rating and a $89 price target, though high valuation multiples and overbought RSI levels pose near-term risks. Earnings growth and BNPL market expansion are key catalysts, while credit losses and competition represent ongoing challenges for shareholders.
ResMed (RMD) trades at $219.75, up 4.83% on the day, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The company reported robust fundamentals with 2025 revenue of $5.15B and net income of $1.40B, supported by a 27.44% net margin. Recent strategic moves include the sale of MatrixCare for $490M and the acquisition of Noctrix Health, sharpening focus on core sleep and respiratory care markets.
Outlook remains positive with a consensus price target of $267.33 implying 21.6% upside, though risks include competitive pressures and integration challenges from recent M&A. The stock's current valuation at 21.06 P/E appears reasonable given growth prospects, but investors should monitor execution on guidance and market share retention amid emerging threats like GLP-1 drugs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Affirm Holdings Inc
Affirm Holdings Inc offers a platform for digital and mobile first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a major share of its revenue from the United States.
Read more on AFRM →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
